[1]Pilleron, S., Sarfati, D., Janssen‐Heijnen, M., Vignat, J., Ferlay, J., Bray, F., & Soerjomataram, I. (2019). Global cancer incidence in older adults, 2012 and 2035: a population‐based study. International journal of cancer, 144(1), 49-58.
[2]Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394-424.
[3]Sullivan, R., Alatise, O. I., Anderson, B. O., Audisio, R., Autier, P., Aggarwal, A., ... & Eggermont, A. M. (2015). Global cancer surgery: delivering safe, affordable, and timely cancer surgery. The lancet oncology, 16(11), 1193-1224.
[4]Snyder, G. L., & Greenberg, S. (2010). Effect of anaesthetic technique and other perioperative factors on cancer recurrence. British journal of anaesthesia, 105(2), 106-115.
[5]Stagg, N. J., Mata, H. P., Ibrahim, M. M., Henriksen, E. J., Porreca, F., Vanderah, T. W., & Malan, T. P. (2011). Regular exercise reverses sensory hypersensitivity in a rat neuropathic pain modelrole of endogenous opioids. Anesthesiology: The Journal of the American Society of Anesthesiologists, 114(4), 940-948.
[6]Zagon, I. S., Verderame, M. F., & McLaughlin, P. J. (2002). The biology of the opioid growth factor receptor (OGFr). Brain Research Reviews, 38(3), 351-376.
[7]Kowalski, J. (1998). Immunologic action of [Met5] enkephalin fragments. European journal of pharmacology, 347(1), 95-99.
[8]Plotnikoff, N. P., Miller, G. C., Nimeh, N., Faith, R. E., Murgo, A. J., & Wybran, J. (1987). Enkephalins and T‐Cell Enhancement in Normal Volunteers and Cancer Patients. Annals of the New York Academy of Sciences, 496(1), 608-619.
[9]Wybran, J., Schandené, L., VAN VOOREN, J. P., Vandermoten, G., Latinne, D., Sonnet, J., ... & Plotnikoff, N. P. (1987). Immunologic Properties of Methionine‐Enkephalin, and Therapeutic Implications in AIDS, ARC, and Cancer. Annals of the New York Academy of Sciences, 496(1), 108-114.
[10]Gan, T. J., Ginsberg, B., Glass, P. S., Fortney, J., Jhaveri, R., & Perno, R. (1997). Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology: The Journal of the American Society of Anesthesiologists, 87(5), 1075-1081.
[11]Maxwell, L. G., Kaufmann, S. C., Bitzer, S., Jackson, E. V., McGready, J., Kost-Byerly, S., ... & Yaster, M. (2005). The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study. Anesthesia & Analgesia, 100(4), 953-958.
[12]Cepeda, M. S., Alvarez, H., Morales, O., & Carr, D. B. (2004). Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects. Pain, 107(1-2), 41-46.
[13]Firouzian, A., Gholipour Baradari, A., Alipour, A., Emami Zeydi, A., Zamani Kiasari, A., Emadi, S. A., ... & Hadadi, K. (2018). Ultra–low-dose naloxone as an adjuvant to patient controlled analgesia (PCA) with morphine for postoperative pain relief following lumber discectomy: a double-blind, randomized, placebo-controlled trial. Journal of neurosurgical anesthesiology, 30(1), 26-31.
[14]Crain, S. M., & Shen, K. F. (2000). Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. PAIN®, 84(2-3), 121-131.
[15]Yang, C. P., Cherng, C. H., Wu, C. T., Huang, H. Y., Tao, P. L., & Wong, C. S. (2011). Intrathecal ultra-low dose naloxone enhances the antinociceptive effect of morphine by enhancing the reuptake of excitatory amino acids from the synaptic cleft in the spinal cord of partial sciatic nerve–transected rats. Anesthesia & Analgesia, 113(6), 1490-1500.
[16]Yao, P., Meng, L., & Gui, J. (1996). Effects of low-dose naloxone on morphine analgesia and plasma leveb of opiold peptldes. Chinese Journal of Anesthesiology, (07).
[17]Aktaş, O. N., Öztürk, A. B., Erman, B., Erus, S., Tanju, S., & Dilege, Ş. (2018). Role of natural killer cells in lung cancer. Journal of cancer research and clinical oncology, 144(6), 997-1003.
[18]Jin, S., Deng, Y., Hao, J. W., Li, Y., Liu, B., Yu, Y., ... & Zhou, Q. H. (2014). NK cell phenotypic modulation in lung cancer environment. PLoS One, 9(10), e109976.
[19]Villegas, F. R., Coca, S., Villarrubia, V. G., Jiménez, R., Chillón, M. J., Jareño, J., ... & Callol, L. (2002). Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung cancer, 35(1), 23-28.
[20]Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., ... & Ugolini, S. (2011). Innate or adaptive immunity? The example of natural killer cells. science, 331(6013), 44-49.
[21]Zamai, L., Ponti, C., Mirandola, P., Gobbi, G., Papa, S., Galeotti, L., ... & Vitale, M. (2007). NK cells and cancer. The Journal of Immunology, 178(7), 4011-4016.
[22]Boland, J. W., McWilliams, K., Ahmedzai, S. H., & Pockley, A. G. (2014). Effects of opioids on immunologic parameters that are relevant to anti-tumour immune potential in patients with cancer: a systematic literature review. British journal of cancer, 111(5), 866.
[23]Deniz, G., van de Veen, W., & Akdis, M. (2013). Natural killer cells in patients with allergic diseases. Journal of Allergy and Clinical Immunology, 132(3), 527-535.
[24]Dehghani, M., Sharifpour, S., Amirghofran, Z., & Zare, H. R. (2012). Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin’s lymphoma patients. Medical Oncology, 29(4), 2364-2371.
[25]Xu, M., Bennett, D. L., Querol, L. A., Wu, L. J., Irani, S. R., Watson, J. C., ... & Klein, C. J. (2018). Pain and the immune system: emerging concepts of IgG-mediated autoimmune pain and immunotherapies. Journal of Neurology, Neurosurgery & Psychiatry, jnnp-2018.
[26]Cardone, D., & Klein, A. A. (2009). Perioperative blood conservation. European Journal of Anaesthesiology (EJA), 26(9), 722-729.
[27]Molenaar, I. Q., Warnaar, N., Groen, H., Tenvergert, E. M., Slooff, M. J. H., & Porte, R. J. (2007). Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta‐analysis. American journal of transplantation, 7(1), 185-194.
[28]Ohira, M., Ohdan, H., Mitsuta, H., Ishiyama, K., Tanaka, Y., Igarashi, Y., & Asahara, T. (2006). Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy. Transplantation, 82(12), 1712-1719.
[29]Gottschalk, A., Sharma, S., Ford, J., Durieux, M. E., & Tiouririne, M. (2010). The role of the perioperative period in recurrence after cancer surgery. Anesthesia & Analgesia, 110(6), 1636-1643.
[30]Wei, G., Moss, J., & Yuan, C. S. (2003). Opioid-induced immunosuppression: is it centrally mediated or peripherally mediated?. Biochemical pharmacology, 65(11), 1761-1766.
[31]Ge, Y. L., Lv, R., Zhou, W., Ma, X. X., Zhong, T. D., & Duan, M. L. (2007). Brain damage following severe acute normovolemic hemodilution in combination with controlled hypotension in rats. Acta Anaesthesiologica Scandinavica, 51(10), 1331-1337.
[32]Barrons, R. W., & Woods, J. A. (2017). Low‐Dose Naloxone for Prophylaxis of Postoperative Nausea and Vomiting: A Systematic Review and Meta‐analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 37(5), 546-554.
[33]Donahue, R. N., McLaughlin, P. J., & Zagon, I. S. (2011). Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Experimental Biology and Medicine, 236(7), 883-895.
[34]Yang, C. P., Cherng, C. H., Wu, C. T., Huang, H. Y., Tao, P. L., Lee, S. O., & Wong, C. S. (2013). Intrathecal ultra-low dose naloxone enhances the antihyperalgesic effects of morphine and attenuates tumor necrosis factor-α and tumor necrosis factor-α receptor 1 expression in the dorsal horn of rats with partial sciatic nerve transection. Anesthesia & Analgesia, 117(6), 1493-1502.
[35]Donahue, R. N., McLaughlin, P. J., & Zagon, I. S. (2011). The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecologic oncology, 122(2), 382-388.
[36]McLaughlin, P. J., & Zagon, I. S. (2012). The opioid growth factor–opioid growth factor receptor axis: Homeostatic regulator of cell proliferation and its implications for health and disease. Biochemical pharmacology, 84(6), 746-755.